Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. ( SLNO ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Anish Bhatnagar - Chairman, President, CEO & COO Meredith Manning - Chief Commercial Officer James MacKaness - CFO & Compliance Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Moritz Reiterer - Guggenheim Securities, LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Soleno: Blockbuster Launch In Progress
Soleno Therapeutics is reassessed after a 24% drop post-VYKAT XR approval enthusiasm. SLNO now faces the critical 'danger zone' between FDA approval and successful commercialization of VYKAT XR for Prader-Willi syndrome. The company's hefty market cap and total reliance on VYKAT XR put it in 'show me' mode for investors.
Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James MacKaness - CFO & Compliance Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with our next fireside discussion.
Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James MacKaness - CFO & Compliance Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Okay. Hi. Good afternoon, everybody.
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James H. MacKaness - CFO & Compliance Officer Meredith Manning - Chief Commercial Officer Conference Call Participants Brian Peter Skorney - Robert W.
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics, Inc. (SLNO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.57 per share a year ago.
Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
